LPCN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LPCN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Lipocine's change in receivables for the quarter that ended in Dec. 2023 was $0.12 Mil. It means Lipocine's Accounts Receivable declined by $0.12 Mil from Sep. 2023 to Dec. 2023 .
Lipocine's change in receivables for the fiscal year that ended in Dec. 2023 was $0.74 Mil. It means Lipocine's Accounts Receivable declined by $0.74 Mil from Dec. 2022 to Dec. 2023 .
Lipocine's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Lipocine's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lipocine's liquidation value for the three months ended in Dec. 2023 was $19.40 Mil.
The historical data trend for Lipocine's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | 0.02 | 0.02 | -4.30 | 0.39 | 0.74 |
Lipocine Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Receivables | Get a 7-Day Free Trial | -0.04 | 0.04 | 0.02 | 0.56 | 0.12 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine (NAS:LPCN) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Lipocine's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0.216 | * | 91 |
= | 0.00 |
2. In Ben Graham's calculation of liquidation value, Lipocine's accounts receivable are only considered to be worth 75% of book value:
Lipocine's liquidation value for the quarter that ended in Dec. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 22.036 | - | 2.632 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 19.40 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Lipocine's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Mahesh V. Patel | director, officer: President and CEO | C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108 |
Richard Dana Ono | director | 18 SPRING ROAD, CONCORD MA 01742 |
Spyridon Papapetropoulos | director | C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608 |
George Nomikos | officer: Chief Medical Officer | 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108 |
Krista Fogarty | officer: Principal Accounting Officer | 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108 |
Jill M. Jene | director | 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451 |
John W. Higuchi | director | C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108 |
Morgan R Brown | officer: EVP and CFO | 420 CHIPETA WAY, SALT LAKE CITY UT 84108 |
Stephen A Hill | director | 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999 |
Jeffrey Arvin Fink | director | 2265 MORNING STAR DRIVE, PARK CITY UT 84060 |
Gregory Brooks Bass | officer: EVP and Chief Commercial Offic | 3228 BROOKSIDE DRIVE, FURLONG PA 18925 |
Jyrki Mattila | officer: Chief Business Officer | AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355 |
Srinivasan Venkateshwaran | officer: CTO and VP RandD | C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108 |
Robert K. Merrell | officer: VP Finance | C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108 |
Gerald T Simmons | officer: VP Corp Business Development | 837 4TH AVE, SALT LAKE CITY UT 84103 |
From GuruFocus
By PRNewswire PRNewswire • 06-14-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire • 08-10-2023
By PRNewswire PRNewswire • 06-24-2022
By PRNewswire • 09-19-2023
By PRNewswire PRNewswire • 07-11-2022
By PRNewswire PRNewswire • 07-06-2022
By PRNewswire • 01-18-2024
By PRNewswire • 10-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.